RATIONALE: Several studies suggest a role for neuropeptide Y (NPY) in addiction to drugs of abuse, including cocaine. However, the NPY receptors mediating addiction-related effects remain to be determined. OBJECTIVES: To explore the potential role of Y5 NPY receptors in cocaine-induced behavioural effects. METHODS: The Y5 antagonist L-152,804 and Y5-knockout (Y5-KO) mice were tested in two models of cocaine addiction-related behaviour: acute self-administration and cocaine-induced hyperactivity. We also studied effects of Y5 receptor antagonism on cocaine-induced c-fos expression and extracellular dopamine with microdialysis as well as dopamine transporter-mediated uptake of dopamine in vitro. Immunocytochemistry was used to determine whether dopamine neurons express Y5-like immunoreactivity. RESULTS: In self-administration, L-152,804 prominently decreased nose-poking for the peak dose of cocaine and shifted the dose-response curve for cocaine downward. Y5-KO mice also showed modestly attenuated self-administration. Cocaine-induced hyperactivity was attenuated by L-152,804 and in Y5-KO mice. Cocaine failed to increase c-fos expression in the nucleus accumbens and striatum of L-152,804-treated mice, indicating that the Y5 antagonist could act by influencing neural activity in these regions. Accordingly, the cocaine-induced increase in accumbal extracellular dopamine was attenuated by L-152,804 and in Y5-KO mice, suggesting that Y5 antagonism influences cocaine-induced behaviour by regulating dopamine. Consistent with this concept, dopamine neurons in the ventral tegmental area appeared to contain Y5 receptors. In contrast, neither L-152,804 nor NPY influenced dopamine transporter-mediated dopamine uptake. CONCLUSIONS: The present data indicate that Y5 antagonism may attenuate cocaine-induced behavioural effects, suggesting that Y5 receptors could be a potential therapeutic target in cocaine addiction.
RATIONALE: Several studies suggest a role for neuropeptide Y (NPY) in addiction to drugs of abuse, including cocaine. However, the NPY receptors mediating addiction-related effects remain to be determined. OBJECTIVES: To explore the potential role of Y5 NPY receptors in cocaine-induced behavioural effects. METHODS: The Y5 antagonist L-152,804 and Y5-knockout (Y5-KO) mice were tested in two models of cocaine addiction-related behaviour: acute self-administration and cocaine-induced hyperactivity. We also studied effects of Y5 receptor antagonism on cocaine-induced c-fos expression and extracellular dopamine with microdialysis as well as dopamine transporter-mediated uptake of dopamine in vitro. Immunocytochemistry was used to determine whether dopamine neurons express Y5-like immunoreactivity. RESULTS: In self-administration, L-152,804 prominently decreased nose-poking for the peak dose of cocaine and shifted the dose-response curve for cocaine downward. Y5-KO mice also showed modestly attenuated self-administration. Cocaine-induced hyperactivity was attenuated by L-152,804 and in Y5-KO mice. Cocaine failed to increase c-fos expression in the nucleus accumbens and striatum of L-152,804-treated mice, indicating that the Y5 antagonist could act by influencing neural activity in these regions. Accordingly, the cocaine-induced increase in accumbal extracellular dopamine was attenuated by L-152,804 and in Y5-KO mice, suggesting that Y5 antagonism influences cocaine-induced behaviour by regulating dopamine. Consistent with this concept, dopamine neurons in the ventral tegmental area appeared to contain Y5 receptors. In contrast, neither L-152,804 nor NPY influenced dopamine transporter-mediated dopamine uptake. CONCLUSIONS: The present data indicate that Y5 antagonism may attenuate cocaine-induced behavioural effects, suggesting that Y5 receptors could be a potential therapeutic target in cocaine addiction.
Authors: Casper R Gøtzsche; Litsa Nikitidou; Andreas T Sørensen; Mikkel V Olesen; Gunnar Sørensen; Søren H O Christiansen; Mikael Ängehagen; David P D Woldbye; Merab Kokaia Journal: Neurobiol Dis Date: 2011-08-22 Impact factor: 5.996
Authors: Gunnar Sørensen; Gregers Wegener; Jørgen Hasselstrøm; Thomas V O Hansen; Gitta Wörtwein; Anders Fink-Jensen; David P D Woldbye Journal: Neuroreport Date: 2009-07-15 Impact factor: 1.837
Authors: Lene S Schmidt; Anthony D Miller; Deranda B Lester; Cecilie Bay-Richter; Christina Schülein; Henriette Frikke-Schmidt; Jürgen Wess; Charles D Blaha; David P D Woldbye; Anders Fink-Jensen; Gitta Wortwein Journal: Psychopharmacology (Berl) Date: 2009-10-10 Impact factor: 4.530
Authors: Ditte Dencker; Pia Weikop; Gunnar Sørensen; David P D Woldbye; Gitta Wörtwein; Jürgen Wess; Anders Fink-Jensen Journal: Psychopharmacology (Berl) Date: 2012-05-31 Impact factor: 4.530
Authors: Gunnar Sørensen; India A Reddy; Pia Weikop; Devon L Graham; Gregg D Stanwood; Gitta Wortwein; Aurelio Galli; Anders Fink-Jensen Journal: Physiol Behav Date: 2015-06-11
Authors: Amy F Eisener-Dorman; Janice S Bailey; Laura Grabowski-Boase; Salvador Huitron-Resendiz; Amanda J Roberts; Tim Wiltshire; Lisa M Tarantino Journal: Psychopharmacology (Berl) Date: 2012-09-05 Impact factor: 4.530
Authors: A Bari; A Dec; A W Lee; J Lee; D Song; E Dale; J Peterson; S Zorn; X Huang; B Campbell; T W Robbins; A R West Journal: Psychopharmacology (Berl) Date: 2014-09-07 Impact factor: 4.530